We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. ArriVent BioPharma, Inc. (AVBP - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
ArriVent BioPharma, Inc. is one of 926 individual stocks in the Medical sector. Collectively, these companies sit at #9 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. ArriVent BioPharma, Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for AVBP's full-year earnings has moved 5% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, AVBP has gained about 23.3% so far this year. In comparison, Medical companies have returned an average of -0.7%. This shows that ArriVent BioPharma, Inc. is outperforming its peers so far this year.
Ocugen (OCGN - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 23%.
Over the past three months, Ocugen's consensus EPS estimate for the current year has increased 5.1%. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, ArriVent BioPharma, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 445 individual companies and currently sits at #88 in the Zacks Industry Rank. This group has gained an average of 6.1% so far this year, so AVBP is performing better in this area. Ocugen is also part of the same industry.
Going forward, investors interested in Medical stocks should continue to pay close attention to ArriVent BioPharma, Inc. and Ocugen as they could maintain their solid performance.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. ArriVent BioPharma, Inc. (AVBP - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
ArriVent BioPharma, Inc. is one of 926 individual stocks in the Medical sector. Collectively, these companies sit at #9 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. ArriVent BioPharma, Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for AVBP's full-year earnings has moved 5% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, AVBP has gained about 23.3% so far this year. In comparison, Medical companies have returned an average of -0.7%. This shows that ArriVent BioPharma, Inc. is outperforming its peers so far this year.
Ocugen (OCGN - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 23%.
Over the past three months, Ocugen's consensus EPS estimate for the current year has increased 5.1%. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, ArriVent BioPharma, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 445 individual companies and currently sits at #88 in the Zacks Industry Rank. This group has gained an average of 6.1% so far this year, so AVBP is performing better in this area. Ocugen is also part of the same industry.
Going forward, investors interested in Medical stocks should continue to pay close attention to ArriVent BioPharma, Inc. and Ocugen as they could maintain their solid performance.